389 related articles for article (PubMed ID: 38558801)
1. Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives.
Levstek L; Janžič L; Ihan A; Kopitar AN
Front Immunol; 2024; 15():1378944. PubMed ID: 38558801
[TBL] [Abstract][Full Text] [Related]
2. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
Lindo L; Wilkinson LH; Hay KA
Front Immunol; 2020; 11():618387. PubMed ID: 33643299
[TBL] [Abstract][Full Text] [Related]
3. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
4. Biobehavioral Implications of Chimeric Antigen Receptor T-cell Therapy: Current State and Future Directions.
Taylor MR; Steineck A; Lahijani S; Hall AG; Jim HSL; Phelan R; Knight JM
Transplant Cell Ther; 2023 Jan; 29(1):19-26. PubMed ID: 36208728
[TBL] [Abstract][Full Text] [Related]
5. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
Sterner RC; Sterner RM
Front Immunol; 2022; 13():879608. PubMed ID: 36081506
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
7. Predictive and therapeutic biomarkers in chimeric antigen receptor T-cell therapy: A clinical perspective.
Mirzaei HR; Mirzaei H; Namdar A; Rahmati M; Till BG; Hadjati J
J Cell Physiol; 2019 May; 234(5):5827-5841. PubMed ID: 30317583
[TBL] [Abstract][Full Text] [Related]
8. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
10. Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy.
Dabas P; Danda A
Med Oncol; 2023 Aug; 40(9):275. PubMed ID: 37608202
[TBL] [Abstract][Full Text] [Related]
11. Identifying and managing CAR T-cell-mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team.
Martino M; Macheda S; Aguglia U; Arcudi L; Pucci G; Martino B; Altomonte M; Rossetti AM; Cusumano G; Russo L; Imbalzano L; Stelitano C; Alati C; Germano' J; Labate D; Amalfi V; Florenzano MT; Morabito A; Borzumati V; Dattola V; Gattuso C; Moschella A; Quattrone D; Curmaci F; Franzutti C; Scappatura G; Rao CM; Loddo V; Pontari A; Pellicano' M; Surace R; Sanguedolce C; Naso V; Ferreri A; Irrera G; Console G; Moscato T; Loteta B; Canale FA; Trimarchi A; Monteleone R; Al Sayyad S; Cirrone F; Bruno B
Expert Opin Biol Ther; 2022 Mar; 22(3):407-421. PubMed ID: 34463175
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma.
Cai F; Zhang J; Gao H; Shen H
Eur J Haematol; 2024 Feb; 112(2):223-235. PubMed ID: 37706523
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review.
Saleh OM; Albakri KA; Alabdallat YJ; Dajani MH; El Gazzar WB
Biomarkers; 2022 Feb; 27(1):22-34. PubMed ID: 34882051
[TBL] [Abstract][Full Text] [Related]
15. Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies.
Zhang G; Deng L; Lu H; Zhang W
Int J Clin Pharm; 2024 Feb; 46(1):186-194. PubMed ID: 38087131
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment.
Nenna A; Carpenito M; Chello C; Nappi P; Annibali O; Vincenzi B; Grigioni F; Chello M; Nappi F
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897819
[TBL] [Abstract][Full Text] [Related]
17. INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies-Established Findings and Future Priorities.
Ligon JA; Ramakrishna S; Ceppi F; Calkoen FGJ; Diorio C; Davis KL; Jacoby E; Gottschalk S; Schultz LM; Capitini CM
Transplant Cell Ther; 2024 Feb; 30(2):155-170. PubMed ID: 37863355
[TBL] [Abstract][Full Text] [Related]
18. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
Celichowski P; Turi M; Charvátová S; Radhakrishnan D; Feizi N; Chyra Z; Šimíček M; Jelínek T; Bago JR; Hájek R; Hrdinka M
J Transl Med; 2023 Mar; 21(1):197. PubMed ID: 36922828
[TBL] [Abstract][Full Text] [Related]
19. [Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
Qian L; Chen J; Wu X; Jing R; Sun J
Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2339-2349. PubMed ID: 31880140
[TBL] [Abstract][Full Text] [Related]
20. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
